The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral treatments for obesity, type 2 diabetes and ...

Health-care companies fell amid concerns about increased regulation and upheaval in the sector. UnitedHealth Group continued its retreat after the abrupt departure of its chief executive.

U.S. health secretary Robert F. Kennedy Jr. said on Wednesday that the "central focus" of the National Institutes of Health ...

What I would say is my opinions about vaccines are irrelevant," Kennedy said. "I don't think people should be taking advice, ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Ubisoft, Tencent Seal Deal Worth $1.25 Billion for Gaming Business French PC game developer Ubisoft has revealed that this ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Zevra Therapeutics shares are trading higher by 6.7% Wednesday morning. The company reported better-than-expected Q1 ...

In a further bid to expand its already lucrative portfolio of metabolic and obesity medicines, Denmark’s Novo Nordisk (NOV: N ...